Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open.

The company will not be hosting a teleconference in conjunction with its financial results press release.

About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to biologically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the 2021 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2022 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:
Investors
Lori Murray, Chief Corporate Affairs Officer
lori.murray@rubiustx.com

Media
Marissa Hanify, Director, Corporate Communications
marissa.hanify@rubiustx.com

Staff

Recent Posts

Greene Concepts Working to Optimize BE WATER Retail Placement Within Walmart Stores

Marion, North Carolina--(Newsfile Corp. - June 20, 2024) - Greene Concepts Inc. (OTC Pink: INKW)…

27 mins ago

Sona’s Therapy Shows Significant Preclinical Efficacy in Second Cancer

Halifax, Nova Scotia--(Newsfile Corp. - June 20, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…

1 hour ago

Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer

SAN DIEGO--(BUSINESS WIRE)--#TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology…

2 hours ago

BSIM Healthcare Services Selects Innovaccer’s Healthcare AI Platform as Foundation for Scaling Value-Based Care Model

Leveraging Innovaccer's healthcare AI platform, BSIM Healthcare Services aims to improve care delivery for underserved…

2 hours ago

EndoSound Vision System™ Granted Transitional CMS Pass-Through Code

PORTLAND, Ore.--(BUSINESS WIRE)--EndoSound®, Inc., is thrilled to announce that the Centers for Medicare & Medicaid…

2 hours ago

Canadian Institute of Actuaries Welcomes New President and Board Members

Ottawa, Ontario--(Newsfile Corp. - June 20, 2024) - The Canadian Institute of Actuaries (CIA) has…

2 hours ago